Caas Capital Management LP Jounce Therapeutics, Inc. Transaction History

Caas Capital Management LP

  • $836 Million
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 16, 2021
SELL
$6.58 - $10.66 $6.93 Million - $11.2 Million
-1,052,437 Closed
0 $0
Q1 2021

May 17, 2021
BUY
$6.73 - $13.87 $7.08 Million - $14.6 Million
1,052,437 New
1,052,437 $10.8 Million

Others Institutions Holding JNCE

# of Institutions
4
Shares Held
720K
Call Options Held
0
Put Options Held
0
View Full List

About Jounce Therapeutics, Inc.

JNCE Quotes by TradingView
  • Ticker JNCE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 51,694,200
  • Description
  • Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...
More about JNCE
Track This Portfolio

Track Caas Capital Management LP Portfolio

Follow Caas Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Caas Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Caas Capital Management LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email